Add to a list

Inactive Instrument

Metsera, Inc. Stock

MTSR

US59267L1070

Biotechnology & Medical Research

Last Transcript: Metsera, Inc.

Metsera, Inc., Pfizer Inc. - M&A Call

25-09-22

More transcripts

Analysts' recommendations: Metsera, Inc.

Nov. 10	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Nov. 10	Pfizer CEO Albert Bourla says Think Co will pay entire CVR for Metsera - CNBC interview	RE
Nov. 10	Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera	MT
Nov. 10	Pfizer wins tug-of-war over Metsera after raising its bid	FW
Nov. 07	Metsera says Pfizer to buy Metsera for up to $86.25 per share	RE

More recommendations

News in other languages: Metsera, Inc.

Nov. 26	Novo Nordisk rebondit après une demande d'approbation aux Etats-Unis
Nov. 25	Novo Nordisk: Kein ruhiges Fahrwasser
Nov. 25	Novo Nordisk: non va tutto liscio
Nov. 25	Novo Nordisk: En vías de recuperación
Nov. 25	Novo Nordisk: geen rustig vaarwater

More news

Metsera Inc is a United States-based biopharmaceutical company. The Company is engaged in developing medicines and solutions for obesity and metabolic diseases. It offers a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with profiles to address multiple therapeutic targets and meet the future needs of a weight loss treatment landscape. Its solutions helps to reduce the physical, emotional, and economic burdens of obesity as a driver of diseases. In addition it offers HALO, which is a peptide lipidation platform technology, which enables peptides to bind simultaneously to albumin and to a drug target.

Employees

129

Sector

Biotechnology & Medical Research

More about the company

Stock markets for all

100% Free Registration

Dec. 12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Dec. 08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Nov. 25	Novo Nordisk Drug Helps Patients Lose Weight, Lower Blood Sugar in Trial -- Update	DJ
Nov. 25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Nov. 25	No plane sailing for Novo Nordisk
Nov. 24	Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer's Trials -- Update	DJ
Nov. 20	Major deals involving U.S. drugmakers and biotechs over the past decade	RE
Nov. 18	Sector Update: Health Care Stocks Higher Tuesday Afternoon	MT
Nov. 18	Pfizer Seeks to Raise $5 Billion in Bond Sale for Metsera Deal	MT
Nov. 18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal	MT
Nov. 18	Pfizer Seeking at Least $5 Billion in Bond Sale for Metsera Deal, Bloomberg Reports	MT
Nov. 16	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Global BMI Index	CI
Nov. 16	Metsera, Inc.(NasdaqGS:MTSR) dropped from S&P Biotechnology Select Industry Index	CI

Nov. 10	Novo Nordisk will not increase its proposal to acquire Metsera, Inc.	AQ
Nov. 08	Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk	AQ
Nov. 07	Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer	PR
Nov. 05	Metsera Issues Statement in Response to Litigation Ruling	PR
Nov. 04	Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer	AQ

1 day	-0.35%
3 months	+111.58%
6 months	+154.42%

Current year	12.3	83.86
1 year	12.3	83.86
3 years	12.3	83.86
5 years	12.3	83.86
10 years	12.3	83.86

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
METSERA, INC.	-0.35%	-.--%	-	-	7.43B
ARGENX SE	+0.58%	-0.29%	+8.22%	+89.48%	49.27B
WUXI APPTEC CO., LTD.	-1.15%	+5.47%	+88.00%	+13.63%	44.15B
INSMED INCORPORATED	-0.16%	-7.12%	+139.36%	+740.41%	34.86B
BIONTECH SE	+1.80%	+9.03%	-2.94%	-24.77%	27.38B
WUXI BIOLOGICS (CAYMAN) INC.	+0.05%	+9.82%	+129.74%	-45.85%	21.21B
GENMAB A/S	-1.11%	+3.58%	+49.92%	-20.24%	21.63B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.86%	+0.26%	+190.73%	-	13.95B
AKESO, INC.	-1.22%	-4.91%	+115.75%	+150.82%	14.58B
SUMMIT THERAPEUTICS INC.	+5.00%	-7.15%	+6.01%	+267.71%	13.61B
Average	+0.43%	+0.77%	+80.53%	+146.40%	26.74B
Weighted average by Cap.	+0.24%	+1.14%	+72.01%	+152.53%

Metsera, Inc. Stock

Equities

MTSR

US59267L1070

Biotechnology & Medical Research

Chart: Metsera, Inc.

Latest news: Metsera, Inc.

Last Transcript: Metsera, Inc.

Analysts' recommendations: Metsera, Inc.

Press Releases: Metsera, Inc.

News in other languages: Metsera, Inc.

Quotes and Performance

Course Extremes

Bio Therapeutic Drugs

Company Profile